Compound glutamine enteric-coated capsules in the treatment and prevention of radiotherapy-and chemotherapy-related intestinal dysfunction in patients with malignant tumors：a systematic review
- VernacularTitle:复方谷氨酰胺肠溶胶囊防治恶性肿瘤患者放化疗相关肠道功能紊乱疗效的系统评价
- Author:
Yuxian CHEN
1
;
Dan ZOU
1
;
Qiaozhi HU
1
Author Information
1. Dept. of Pharmacy，West China Hospital of Sichuan University，Chengdu 610041，China
- Publication Type:Journal Article
- Keywords:
Compound glutamine enteric-coated capsules
- From:
China Pharmacy
2026;37(8):1068-1073
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the efficacy of Compound glutamine enteric-coated capsules in the treatment and prevention of radiotherapy- and chemotherapy-related intestinal dysfunction in patients with malignant tumors. METHODS PubMed， Embase， CNKI， and Wanfang data were searched to collect randomized controlled trial （RCT） and cohort studies comparing Compound glutamine enteric-coated capsules （experimental group） with or without other treatments versus other treatments or blank control （control group）. The search period was from the establishment of each database to November 19， 2025. After literature screening， data extraction， and quality assessment， a meta-analysis was performed using RevMan 5.4 software. RESULTS A total of 23 studies were included， involving 2 014 patients. Meta-analysis results showed that the effective rate in the experimental group was significantly higher than that in the control group， the overall incidence and moderate-to-severe incidence of radiotherapy- and chemotherapy-related intestinal dysfunction， quality of life scores， and interleukin-6 levels in the experimental group were significantly lower than those in the control group （ P ＜0.05）. However， no statistically significant differences were observed between the two groups in terms of Karnofsky Performance Status score improvement rate and tumor necrosis factor-α levels （ P ＞0.05）. The results of subgroup analysis based on different medications in the control group showed that， when used for treatment， regardless of whether patients in the control group received blank control or positive control， the efficacy in the experimental group was significantly higher than that in the control group （ P ＜0.05）. When used for prevention， compared with patients who received blank control in the control group， the overall incidence and the incidence of moderate-to-severe radiotherapy- and chemotherapy-related intestinal dysfunction in the experimental group were significantly reduced （ P ＜0.05）. No statistically significant difference was found in the overall incidence or incidences of moderate-to-severe radiotherapy- and chemotherapy-related intestinal dysfunction with positive control between the two groups （ P ＞0.05）. CONCLUSIONS Compound glutamine enteric-coated capsules can effectively treat and prevent radiotherapy- and chemotherapy-related intestinal dysfunction in patients with malignant tumors， improve patients’ quality of life， and alleviate inflammatory responses.
